Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Directors Deals Ltd.
$12.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

arGEN X BV announces positive preclinical results for ARGX-113


Tuesday, 19 Aug 2014 07:53am EDT 

arGEN X BV:Announces the results of a preclinical study assessing the pharmacokinetic and pharmacodynamic (PK/PD) behaviors of ARGX-113.Says the data proved ARGX-113 to be highly effective in rapidly clearing a tracer antibody from circulation in a dose-dependent manner in non-human primates, thus acting as a surrogate of autoantibody clearance.Says ARGX-113 is a proprietary antibody fragment based on the company's ABDEG(TM) technology, which modulates the process of antibody recycling.Says expects to submit a Clinical Trial Application (CTA) for ARGX-113 to the applicable regulatory body in the second half of 2015, proposing the initiation of a Phase 1 study in healthy volunteers to establish safety and tolerability of the drug.